NASDAQ:MNOV

MediciNova (MNOV) Stock Price, News & Analysis

MediciNova logo
$1.31 +0.04 (+3.15%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.31 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About MediciNova Stock (NASDAQ:MNOV)

Advanced

Key Stats

Today's Range
$1.27
▼
$1.32
50-Day Range
$1.27
▼
$3.45
52-Week Range
$1.22
▼
$3.90
Volume
48,973 shs
Average Volume
57,252 shs
Market Capitalization
$67.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.75
Consensus Rating
Moderate Buy

Company Overview

MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

AI Generated. May Contain Errors.

MediciNova Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

MNOV MarketRank™: 
2.81214927048 of 5 stars

MediciNova scored higher than 56% of companies evaluated by MarketBeat, and ranked 398th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MediciNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    MediciNova has a consensus price target of $7.75, representing about 491.6% upside from its current price of $1.31.

  • Amount of Analyst Coverage

    MediciNova has only been the subject of 3 research reports in the past 90 days.

  • Read more about MediciNova's stock forecast and price target.
  • Earnings Growth

    Earnings for MediciNova are expected to decrease in the coming year, from ($0.22) to ($0.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MediciNova is -6.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MediciNova is -6.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MediciNova has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.67% of the float of MediciNova has been sold short.
  • Short Interest Ratio / Days to Cover

    MediciNova has a short interest ratio ("days to cover") of 5.44.
  • Change versus previous month

    Short interest in MediciNova has recently decreased by 2.44%, indicating that investor sentiment is improving.
  • Dividend Yield

    MediciNova does not currently pay a dividend.

  • Dividend Growth

    MediciNova does not have a long track record of dividend growth.

  • News Sentiment

    MediciNova has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for MediciNova this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, MediciNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,728,000.00 in company stock.

  • Percentage Held by Insiders

    14.00% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    9.90% of the stock of MediciNova is held by institutions.

  • Read more about MediciNova's insider trading history.
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MNOV Stock News Headlines

MediciNova FY2026 Earnings Forecast Boosted by HC Wainwright
Medicinova Inc
Seven bucks, yours for life: my Black Friday indicator deal
Base Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade.tc pixel
MediciNova to Participate in the Maxim Growth Summit
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More Headlines

MNOV Stock Analysis - Frequently Asked Questions

MediciNova's stock was trading at $1.31 at the start of the year. Since then, MNOV shares have increased by 0.0% and is now trading at $1.31.

MediciNova, Inc. (NASDAQ:MNOV) issued its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.00. The biopharmaceutical company earned $138.56 thousand during the quarter, compared to analyst estimates of $50 thousand. MediciNova had a negative net margin of 1,126.60% and a negative trailing twelve-month return on equity of 26.47%.

Top institutional shareholders of MediciNova include Goldman Sachs Group Inc. (1.25%), State Street Corp (0.39%), Empowered Funds LLC (0.10%) and Jump Financial LLC (0.04%).
View institutional ownership trends
.

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MediciNova investors own include NVIDIA (NVDA), Nokia (NOK), Ideanomics (IDEX), SNDL (SNDL), Tonix Pharmaceuticals (TNXP), Ford Motor (F) and GE Aerospace (GE).

Company Calendar

Last Earnings
11/12/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MNOV
CIK
1226616
Employees
6
Year Founded
2000

Price Target and Rating

High Price Target
$10.00
Low Price Target
$6.00
Potential Upside/Downside
+491.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12 million
Net Margins
-1,126.60%
Pretax Margin
-1,126.07%
Return on Equity
-26.47%
Return on Assets
-24.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.75
Quick Ratio
8.75

Sales & Book Value

Annual Sales
$935.72 thousand
Price / Sales
71.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.80 per share
Price / Book
1.64

Miscellaneous

Outstanding Shares
51,233,000
Free Float
44,060,000
Market Cap
$67.12 million
Optionable
Optionable
Beta
0.71

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:MNOV) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners